0H22 vs 5GV: Side-by-Side Comparison
Compare Bioinvent International AB (0H22) and GENOVIS AB SE-40 (5GV) side by side: valuation, financials, growth and model signals on Bullrun.
| Metric | 0H22 | 5GV |
|---|---|---|
| Company | Bioinvent International AB | GENOVIS AB SE-40 |
| Country / Exchange | Sweden · LSE | Sweden · F |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
| Market cap | — | EUR 110.59M |
| P/E ratio | — | 55.8 |
| Dividend yield | — | — |
| Valuation model | — | 41.3% overvalued |
| Revenue (latest FY) | — | — |
| Revenue growth YoY | — | — |
| Net income | — | — |
| Gross margin | — | — |
| Diluted EPS | — | — |